211 related articles for article (PubMed ID: 10779027)
1. Low-molecular-weight heparin in thrombotic disease in children and adolescents.
Punzalan RC; Hillery CA; Montgomery RR; Scott CA; Gill JC
J Pediatr Hematol Oncol; 2000; 22(2):137-42. PubMed ID: 10779027
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
Massicotte P; Adams M; Marzinotto V; Brooker LA; Andrew M
J Pediatr; 1996 Mar; 128(3):313-8. PubMed ID: 8774496
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Enoxart Study Group.
Samama CM; Gigou F; Ill P
Ann Vasc Surg; 1995; 9 Suppl():S45-53. PubMed ID: 8688309
[TBL] [Abstract][Full Text] [Related]
5. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
7. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
Bergmann JF; Neuhart E
Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
[TBL] [Abstract][Full Text] [Related]
8. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
[TBL] [Abstract][Full Text] [Related]
9. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
10. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
De A; Roy P; Garg VK; Pandey NK
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
[TBL] [Abstract][Full Text] [Related]
13. Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery.
Renda G; Di Pillo R; D'Alleva A; Sciartilli A; Zimarino M; De Candia E; Landolfi R; Di Giammarco G; Calafiore A; De Caterina R
Haematologica; 2007 Mar; 92(3):366-73. PubMed ID: 17339186
[TBL] [Abstract][Full Text] [Related]
14. Heparin versus enoxaparin for prevention of venous thromboembolism after trauma: A randomized noninferiority trial.
Olson EJ; Bandle J; Calvo RY; Shackford SR; Dunne CE; Van Gent JM; Zander AL; Sikand H; Bongiovanni MS; Sise MJ; Sise CB
J Trauma Acute Care Surg; 2015 Dec; 79(6):961-8; discussion 968-9. PubMed ID: 26317819
[TBL] [Abstract][Full Text] [Related]
15. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Corder A; Held K; Oschman A
Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
[TBL] [Abstract][Full Text] [Related]
16. Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.
Siddiqui MA; Wagstaff AJ
Drugs; 2005; 65(7):1025-36. PubMed ID: 15892594
[TBL] [Abstract][Full Text] [Related]
17. Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover.
Roschitz B; Beitzke A; Gamillscheg A; Sudi K; Koestenberger M; Leschnik B; Muntean W
Thromb Res; 2003; 111(6):335-41. PubMed ID: 14698650
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
[TBL] [Abstract][Full Text] [Related]
19. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
Colwell CW; Spiro TE; Trowbridge AA; Morris BA; Kwaan HC; Blaha JD; Comerota AJ; Skoutakis VA
J Bone Joint Surg Am; 1994 Jan; 76(1):3-14. PubMed ID: 8288662
[TBL] [Abstract][Full Text] [Related]
20. Unfractionated heparin dosing requirements in the presence of inflammation during the first six months of life.
Heizer JW; Schardt TQ; Murphy ME; Branchford BR
Thromb Res; 2019 May; 177():17-22. PubMed ID: 30844684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]